Immunoblot and enzyme-activity analyses, using specific immunological probes, indicated that more than 80% of the total low-Km cAMP phosphodiesterase activity present in bovine and human platelets resided in a single phosphodiesterase isozyme. In the presence of protease inhibitors, the platelet enzyme has an apparent subunit size of 110 kDa and appears immunologically and structurally indistinguishable from a recently purified bovine heart isozyme. When protease inhibitors were absent during homogenization and centrifugation, this platelet phosphodiesterase was susceptible to sequential proteolysis forming 80-kDa and 60-kDa peptides. As a previous report on the purification of the platelet low-Km cAMP phosphodiesterase described a 61-kDa protein, our data would suggest that this was a proteolytic fragment. Moreover, in our study a 40-70% increase in catalytic activity was associated with proteolysis. Further similarities between the platelet and heart phosphodiesterases were demonstrated by pharmacological studies that showed identical inhibitor profiles for both enzymes. Several known phosphodiesterase inhibitor compounds that have been found useful in inhibiting platelet aggregation also inhibited the platelet low-Km cAMP phosphodiesterase with potencies very similar to their antithrombotic effects. Cilostamide, Ro 15-2041, milrinone, papaverine, isobutylmethylxanthine, and theophylline inhibited the 110-kDa platelet enzyme with IC50 values of 0.04, 0.13, 0.46, 1.4, 2.6, and 110 ,uM, respectively.
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The hydrolysis of the important cytosolic "second messenger" molecules, cAMP and cGMP, is now known to be carried out by several phosphodiesterase isozymes. These differ from one another in terms of their regulation, substrate affinities, and rates of hydrolysis (1) . Platelets have been reported to contain three different phosphodiesterase forms (2, 3) : the first was relatively specific for cGMP, whereas the second appeared to be nonselective. The third, however, seemed to preferentially hydrolyze cAMP and has been reported in its purified form to be a low-Km enzyme of61-kDa by NaDodSO4/PAGE analysis (4) .
Since platelet responsiveness appears to depend on a balance between signal-transducing pathways that lead to changes in cytosolic free Ca2+ or cAMP (5) , the regulation of cAMP levels is crucial to the control of platelet function. Calcium-mobilizing agonists (e.g., thrombin or thromboxane A2) promote platelet activation, whereas agents that increase cellular cAMP concentrations (e.g., prostacyclin or prostaglandin E1) act to inhibit platelet function (5, 6) . This opposing effect of elevated cAMP levels has prompted investigation into the development of compounds that could selectively inhibit platelet cAMP phosphodiesterase activity and act as antithrombotic agents. Cilostamide (3) and Ro 15-2041 (7) are two potent inhibitors of platelet aggregation and have been shown recently to be equally effective inhibitors of the platelet low-Km cAMP phosphodiesterase (the so-called "F III phosphodiesterase"; ref. 3) .
A major goal of many investigators has been the purification of this cAMP phosphodiesterase present in platelets. This would lead to a greater understanding of how the enzyme functions and allow the production of specific monoclonal antibodies, probes that would allow further characterization of the isozyme. Such information would undoubtedly aid the formulation of selective inhibitors for possible use as antithrombotic agents.
A novel low Km cAMP phosphodiesterase isozyme has been purified in our laboratory from bovine heart (8) . This enzyme has been designated as cGMP-inhibited phosphodiesterase, since low concentrations of cGMP inhibit (Ki = 6 x 10-8 M) cAMP hydrolysis. This paper demonstrates, through immunological, physical, and pharmacological studies, that the platelet low-Km cAMP phosphodiesterase appears identical to the recently purified isozyme from bovine heart. The implications of this finding are discussed with regard to the cellular regulation of the enzyme and its role in the mechanism of action of antithrombotic agents in the treatment of ischemic heart disease. Platelet Preparation and Fractionation. Bovine platelet suspensions were prepared from 800 ml of fresh blood collected in 200 ml ofbuffer containing 1.33 g of EDTA, 0.9% saline, and 2 g ofglucose (pH 7.4). This was centrifuged at 900 x g for 6 min at room temperature, and the resulting platelet-rich plasma was recentrifuged at 400 x g to remove contaminating leukocytes and erythrocytes. Platelets were then sedimented at 2200 x g for 9 min and washed three times by resuspension/centrifugation in isotonic Tris-buffered saline (pH 7.4) containing 135 mM NaCl, 20 mM Tris HCl, 13 mM sodium citrate, 5 mM glucose, and 2 mM EDTA. The resulting bovine platelet pellet (0.4-0.5 g wet weight) was resuspended in 7 ml of homogenization buffer (40 mM Tris'HCl, pH 7.8/15 mM 2-mercaptoethanol/50 mM benzamidine HCl/20 ,ug of leupeptin per ml at 4°C) and homogenized by sonication (Branson Sonic Power sonifier, 65% intensity) twice for 15 sec. In some experiments the platelet pellet was split into two portions and homogenized in 3.5 ml of buffer with or without benzamidine and leupeptin. Homogenates were centrifuged at 40,000 x g for 30 min at 4°C in a Beckman 75 Ti ultracentrifuge rotor. The resulting pellet was washed once by resuspension/centrifugation in 10 ml of 6660
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homogenization buffer and finally resuspended in the original supernatant volume.
Human platelets were obtained from healthy donors and prepared by the method of Ardlie et al. (9) . Platelets were washed once with the wash buffer described above before homogenization (5 x 109 per ml) and centrifugation as outlined for bovine platelets. DEAE-Cellulose Chromatography. A 5-ml fraction of bovine platelet supernatant from centrifugation at 40,000 x g was applied to a 2.5-ml DEAE-cellulose column equilibrated in 50 mM Tris HCl, pH 7.8/2 mM EDTA/15 mM 2-mercaptoethanol/0.1 M NaCl. The column was then washed with 20 ml of the same equilibrating buffer. Elution was performed with a 10-ml linear NaCl gradient (0.1-0.7 M), and 0.5-ml fractions were collected.
Immunoadsorption and Immunoblot Analysis. Solid-phase antibody reagents (Pansorbin-based) were prepared by using a specific monoclonal antibody (CGI-5; ref. 8) directed against the cGMP-inhibited phosphodiesterase from bovine heart. These procedures have been described in detail (8, 10) . A monoclonal antibody (ROS-1; ref. 11) directed against a phosphodiesterase isolated from the bovine rod outer segment, but ofthe same immunoglobulin subtype as CGI-5, was used to measure nonspecific adsorption of platelet supematant phosphodiesterase activity. Such adsorption was equivalent or less than adsorption produced with solid-phase reagent in the absence of primary antibody (data not shown).
For immunoblot analysis, platelet pellet or supernatant fractions were boiled in an equal volume of sample buffer containing NaDodSO4. Samples were analyzed by NaDod-S04/PAGE on a 10% gel (12) . Protein transfer to nitrocellulose and subsequent immunoblotting procedures have been described elsewhere (8) . Controls were performed with preimmune sera or control monoclonal antibody and produced essentially blank autoradiograms (data not shown).
Phosphodiesterase Assay and Inhibitor Study. Phosphodiesterase activity was assayed at 30°C as described (10) . Rates ofhydrolysis were linear over the range oftimes and dilutions used. Monoclonal antibody-phosphodiesterase complexes were prepared from platelet supernatants and used in inhibitor studies. Such complexes have been shown not to interfere with phosphodiesterase catalytic activity and, therefore, are ideal for conducting inhibitor studies against one specific enzyme (8, 10) . Control experiments demonstrated that the drug vehicles did not interfere with the phosphodiesterase assay and also that none of the inhibitors tested affected snake venom activity necessary for the assay. Finally, protein determinations were performed by the method of Bradford (13) with bovine serum albumin (Sigma) as standard.
RESULTS
Identification of the Phosphodiesterase as a 110-kDa Protein.
When bovine platelet cAMP phosphodiesterase activity was measured at 1 AM substrate after homogenization and centrifugation, -85% ofthe activity was found in the supernatant at 40,000 x g as compared to l15% in the pellet (Fig. LA) . Almost 90% of this supernatant activity was specifically immunoadsorbed after incubation with a solid-phase monoclonal antibody (CGI-5; ref. 8 ) directed against a bovine heart low-Km cAMP phosphodiesterase (Fig. 1B) .
Immunoblot analysis of the bovine platelet supernatant with CGI-5 monoclonal antibody showed that the phosphodiesterase had an apparent subunit molecular mass of 110 kDa (Fig. 1C, lane 1) . This was identical to that of the bovine heart enzyme (Fig. 1C, lane 5) . A quantitatively much weaker 110-kDa signal was observed from the immunoblot of the particulate fraction (Fig. 1C, lane 2) , suggesting that at least a portion of the activity associated with the pellet was contributed by the 110-kDa protein. Lanes 3 and 4 in Fig. 1C show that a close correlation existed between specific immunoprecipitation of supernatant activity by CGI-5 and a reduction in the 110-kDa blotting signal.
Human platelets were similarly fractionated and subjected to the same analyses. In addition to identifying the phosphodiesterase as a 110-kDa peptide, the percentage of total activity that was soluble and the specific immunoadsorption of activity by CGI-5 were identical for both bovine and human platelets (Fig. 1C, lanes 6 and 7; also data not shown).
Bovine platelet supernatant was applied to a DE-52 cellulose column and eluted with a linear NaCl gradient; fractions were assayed for cAMP phosphodiesterase at 1 ,iM substrate (Fig. 2) . The profile obtained was similar to those previously reported (3, 4) performed heart enzyme instead of CGI-5, since the former did not recognize the 60-kDa protein (data not shown). In the presence of protease inhibitors, the only major signal at all time points studied was the 110-kDa peptide (Fig. 3, lanes  1-4) . However, in the absence of protease inhibitors, the immunoblot pattern was significantly altered (Fig. 3, lanes  5-8) . Even at zero time, marked proteolysis was evident with the appearance of two fragments at 80 kDa and 60 kDa (Fig.  3, lanes 5 and 7) . Most of the reduction in the 110-kDa signal at this time point seemed to be recovered in the 80-kDa band. At longer incubations, the intensity of the 60-kDa signal was further increased (Fig. 3, lanes 6 and 8) . After 6 hr of incubation, the intensity of the total signal was reduced, suggesting breakdown to even smaller fragments, which were not recognized by the antiserum. Finally, it should be noted that concomitant with proteolysis at zero time was a 40-70% increase in low-Km cAMP phosphodiesterase activity.
Inhibitor Studies. Table 1 shows IC50 values for the inhibition of bovine low-Km cAMP phosphodiesterase by several inhibitors of phosphodiesterase. Cilostamide, Ro 15-2041, cGMP, and milrinone were all potent inhibitors of platelet cAMP phosphodiesterase with IC50 values of 0.04, 0.13, 0.13, and 0.46 ,uM, respectively. In contrast, both theophylline and Ro 20-1724 were more than 2 orders of magnitude less potent. Furthermore, the values given for cGMP, milrinone, papaverine, isobutylmethylxanthine, and Ro 20-1724 are in close agreement with inhibitor data obtained with the bovine heart isozyme (8, 10).
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The finding that two potent inhibitors of platelet aggregation, cilostamide and Ro 15-2041, were also potent inhibitors of platelet cAMP phosphodiesterase (refs. 3 and 7 and this study) is of some interest. First, both these drugs, like milrinone (16) , have stimulatory effects on myocardial contractility (7, 17) . Second, from the results presented in this paper, milrinone, like cilostamide and Ro 15-2041, would be expected to be a potent inhibitor of platelet aggregation. Third, a close connection is beginning to emerge between antithrombotic agents, which are cAMP phosphodiesterase inhibitors, and their use in the treatment of ischemic heart disease (18, 19) . It is tempting to speculate that the locus of such an action lies at the level of cGMP-inhibited phosphodiesterase.
It has been demonstrated that neither cilostamide nor Ro 15-2041 is able to increase basal cAMP concentrations in platelets. However, both were able to inhibit agonist-induced aggregation and potentiate the increase in platelet cAMP concentration stimulated by prostacyclin or prostaglandin E1 (3, 7) . These data support the idea that two pools of cAMP exist in platelets (15) . One of these is thought to be a small functional pool that is sensitive to the action oflow-Km cAMP phosphodiesterase inhibitors. A similar observation was noted with adipocytes, where cilostamide was found to promote lipolysis (20) . In this particular study, cilostamide was used to selectively inhibit the insulin-sensitive low-Km cAMP phosphodiesterase. This adipocyte phosphodiesterase is also inhibited by low concentrations of both cGMP and milrinone and, interestingly, has been immunoadsorbed by antiserum to the bovine heart low-Km isozyme (21) .
Finally, incubation of intact platelets with either prostacyclin or prostaglandin E1 leads to an activation of low-Km cAMP phosphodiesterase activity (22, 23) . This activation has been postulated as a negative-feedback regulation of agonist-induced increases in cAMP levels. Furthermore, some findings suggest that activation of a cAMP-dependent protein kinase is an intermediate step (23, 24) .
